Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Reszegi

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Acta Pharmaceutica Hungarica|December 1, 2005
[Utilization study of clozapine, olanzapine and risperidone in Hungary]András Klebovich, Csilla Andrea Reszegi, Romána Zelkó
International Journal of Molecular Sciences|December 23, 2023
Insights into the Tumor Microenvironment-Components, Functions and TherapeuticsKornélia Baghy, Andrea Ladányi, Andrea Reszegi, et al.
Advances in Experimental Medicine and Biology|August 27, 2020
Decorin in the Tumor MicroenvironmentKornélia Baghy, Andrea Reszegi, Péter Tátrai, et al.
American Journal of Physiology. Cell Physiology|June 15, 2022
Syndecan-1 in liver pathophysiologyAndrea Reszegi, Péter Tátrai, Eszter Regős, et al.
American Journal of Physiology. Cell Physiology|March 2, 2022
SPOCK1 with unexpected function. The start of a new careerLórand Váncza, Péter Tátrai, Andrea Reszegi, et al.
Acta Pharmaceutica Hungarica|December 2, 2005
[Practice of antidiabetic therapy in Hungary]Balázs Zoltán Hankó, Csilla Andrea Reszegi, Péter Kumli, et al.
Cellular Signalling|July 5, 2019
Tumor-specific inhibitory action of decorin on different hepatoma cell linesZsolt Horváth, Andrea Reszegi, László Szilák, et al.
Frontiers in Oncology|June 2, 2020
Protective Role of Decorin in Primary Hepatocellular CarcinomaAndrea Reszegi, Zsolt Horváth, Hajnalka Fehér, et al.
Pathology Oncology Research : POR|March 4, 2019
Syndecan-1 in Liver DiseasesEszter Regős, Katalin Karászi, Andrea Reszegi, et al.
Acta Oncologica (Stockholm, Sweden)|January 25, 2021
Identification of a novel resistance mechanism in venetoclax treatment and its prediction in chronic lymphocytic leukemiaFerenc Takács, Gábor Mikala, Noémi Nagy, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Acta Pharmaceutica Hungarica|December 1, 2005
[Utilization study of clozapine, olanzapine and risperidone in Hungary]András Klebovich, Csilla Andrea Reszegi, Romána Zelkó
International Journal of Molecular Sciences|December 23, 2023
Insights into the Tumor Microenvironment-Components, Functions and TherapeuticsKornélia Baghy, Andrea Ladányi, Andrea Reszegi, et al.
Advances in Experimental Medicine and Biology|August 27, 2020
Decorin in the Tumor MicroenvironmentKornélia Baghy, Andrea Reszegi, Péter Tátrai, et al.
American Journal of Physiology. Cell Physiology|June 15, 2022
Syndecan-1 in liver pathophysiologyAndrea Reszegi, Péter Tátrai, Eszter Regős, et al.
American Journal of Physiology. Cell Physiology|March 2, 2022
SPOCK1 with unexpected function. The start of a new careerLórand Váncza, Péter Tátrai, Andrea Reszegi, et al.
Acta Pharmaceutica Hungarica|December 2, 2005
[Practice of antidiabetic therapy in Hungary]Balázs Zoltán Hankó, Csilla Andrea Reszegi, Péter Kumli, et al.
Cellular Signalling|July 5, 2019
Tumor-specific inhibitory action of decorin on different hepatoma cell linesZsolt Horváth, Andrea Reszegi, László Szilák, et al.
Frontiers in Oncology|June 2, 2020
Protective Role of Decorin in Primary Hepatocellular CarcinomaAndrea Reszegi, Zsolt Horváth, Hajnalka Fehér, et al.
Pathology Oncology Research : POR|March 4, 2019
Syndecan-1 in Liver DiseasesEszter Regős, Katalin Karászi, Andrea Reszegi, et al.
Acta Oncologica (Stockholm, Sweden)|January 25, 2021
Identification of a novel resistance mechanism in venetoclax treatment and its prediction in chronic lymphocytic leukemiaFerenc Takács, Gábor Mikala, Noémi Nagy, et al.
Pageof 3